Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on May 27, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in San Antonio, Texas. Its common stock (BIAF) and tradeable warrants (BIAFW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing discloses specific equity figures derived from the Company's most recent Quarterly Report on Form 10-Q (filed May 15, 2025):
- Stockholders' Equity: $1,439,404 as of March 31, 2025.
- Minimum Equity Requirement: $2,500,000 (Nasdaq Listing Rule 5550(b)(1)).
- Market Value of Listed Securities: The filing states the Company does not meet the $35 million alternative standard.
- Net Income: The filing states the Company does not meet the $500,000 net income from continued operations standard for the most recent fiscal year or two of the last three fiscal years.
The filing text does not provide clear values for revenue, cash flow, operating margins, or total debt.
Material Changes and Listing Status
On May 27, 2025, the Company received written notice from Nasdaq stating it is not in compliance with the Stockholders' Equity Requirement due to equity falling below the $2.5 million threshold. This is a separate deficiency from a previously disclosed "Minimum Bid Price Deficiency Letter" received on February 7, 2025, regarding failure to maintain a $1.00 minimum closing bid price.
Despite the notice, the Company's stock will continue to trade on the Nasdaq Capital Market under the symbol "BIAF" pending compliance actions.
Outlook, Management Commentary, and Risks
Compliance Timeline: The Company has 45 calendar days (until July 11, 2025) to submit a Compliance Plan to regain compliance. If accepted, Nasdaq may grant an extension of up to 180 calendar days from May 27, 2025, to restore equity levels.
Management Intent: The Company intends to submit a plan and monitor stockholders' equity, considering further options to regain compliance. However, management notes there can be no assurance the plan will be accepted.
Risks and Contingencies: If the Compliance Plan is not accepted or if the Company fails to regain compliance within the extension period, the Company will have the right to a hearing before Nasdaq's Hearing Panel. Failure to resolve these deficiencies could result in suspension or delisting.
Key Facts for Investor Verification
- Verify the specific details of the Compliance Plan to be submitted by July 11, 2025.
- Monitor the Company's stock price to assess progress on the separate Minimum Bid Price deficiency.
- Review the Form 10-Q filed on May 15, 2025, for full details on the $1,439,404 stockholders' equity balance.
- Track any announcements regarding the acceptance of the Compliance Plan by Nasdaq.
- Assess the Company's ability to raise capital or improve operations to meet the $2.5 million equity requirement within the 180-day extension window.